{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower and upper confidence interval could not be calculated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"RFS was defined as the time from the documentation of CR to disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"MEDIAN","populationDescription":"Participants in the all-treated population who achieved CR.","reportingStatus":"POSTED","timeFrame":"Up to 39 months","title":"Relapse-free Survival (RFS)","type":"SECONDARY","unitOfMeasure":"months"}